A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 11-55 YEAR OLD SUBJECTS WITH MENACWY-TT OR MENCEVAX (REGISTERED) ACWY
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
- Indications Meningococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; Pfizer
- 25 Oct 2020 Results of pooled analysis (of data pooled from NCT01934140 and NCT03189745 studies) assessing the long-term persistence of MenACWY-TT immune responses in adolescents as well as safety and immunogenicity of a booster dose given 10 years after primary vaccination presented at the IDWeek 2020
- 10 Sep 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.